Oak Street Health (NYSE:OSH – Get Rating) was downgraded by Bank of America from a “buy” rating to an “underperform” rating in a report released on Wednesday, The Fly reports.
OSH has been the subject of several other research reports. SVB Leerink lifted their price target on Oak Street Health from $17.00 to $23.00 and gave the stock a “market perform” rating in a research report on Wednesday, March 2nd. Piper Sandler lowered their price target on Oak Street Health from $47.00 to $43.00 and set an “overweight” rating for the company in a research report on Wednesday, March 2nd. Sanford C. Bernstein assumed coverage on Oak Street Health in a research report on Thursday, May 26th. They issued an “outperform” rating and a $26.00 price target for the company. Guggenheim assumed coverage on Oak Street Health in a research report on Tuesday, March 29th. They issued a “neutral” rating for the company. Finally, Barclays lifted their price objective on Oak Street Health from $27.00 to $31.00 and gave the stock an “overweight” rating in a report on Tuesday, April 19th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $35.27.
NYSE:OSH opened at $15.75 on Wednesday. The stock has a market cap of $3.80 billion, a P/E ratio of -7.95 and a beta of 2.40. The firm’s fifty day simple moving average is $19.54 and its 200 day simple moving average is $22.68. Oak Street Health has a twelve month low of $13.29 and a twelve month high of $65.22. The company has a quick ratio of 1.79, a current ratio of 1.79 and a debt-to-equity ratio of 16.10.
Oak Street Health (NYSE:OSH – Get Rating) last announced its quarterly earnings data on Tuesday, May 3rd. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.04). The firm had revenue of $513.80 million for the quarter, compared to analysts’ expectations of $506.82 million. Oak Street Health had a negative net margin of 26.82% and a negative return on equity of 413.94%. The business’s quarterly revenue was up 73.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.29) EPS. On average, analysts expect that Oak Street Health will post -2.2 EPS for the current fiscal year.
In related news, insider Geoffrey M. Price sold 120,000 shares of the stock in a transaction on Tuesday, May 31st. The stock was sold at an average price of $18.91, for a total transaction of $2,269,200.00. Following the sale, the insider now owns 1,893,270 shares in the company, valued at approximately $35,801,735.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Geoffrey M. Price sold 60,000 shares of the stock in a transaction on Tuesday, April 5th. The shares were sold at an average price of $26.56, for a total value of $1,593,600.00. Following the sale, the insider now owns 3,871,377 shares in the company, valued at approximately $102,823,773.12. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 380,000 shares of company stock valued at $8,478,400. 11.40% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the company. The Manufacturers Life Insurance Company bought a new position in shares of Oak Street Health during the 1st quarter worth $950,000. Capital Research Global Investors raised its stake in Oak Street Health by 61.0% in the first quarter. Capital Research Global Investors now owns 11,852,080 shares of the company’s stock valued at $318,584,000 after buying an additional 4,491,941 shares during the last quarter. Capital Group Private Client Services Inc. raised its stake in Oak Street Health by 18.2% in the first quarter. Capital Group Private Client Services Inc. now owns 225,108 shares of the company’s stock valued at $6,051,000 after buying an additional 34,739 shares during the last quarter. Weiss Multi Strategy Advisers LLC purchased a new stake in Oak Street Health in the first quarter valued at about $383,000. Finally, Eminence Capital LP purchased a new stake in Oak Street Health in the first quarter valued at about $73,233,000. 91.42% of the stock is currently owned by institutional investors and hedge funds.
About Oak Street Health (Get Rating)
Oak Street Health, Inc, together with its subsidiaries, offers healthcare services to the patients in the United States. The company operates primary care centers for Medicare beneficiaries. As of December 31, 2021, it operated 129 centers in 19 states, including Illinois, Michigan, Pennsylvania, Ohio, and Texas.
Further Reading
Receive News & Ratings for Oak Street Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Oak Street Health and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
